MSA
PCRX icon

Mason Street Advisors’s Pacira BioSciences PCRX Stock Holding History

Mason Street Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,200
Closed -$969K – 891
2020
Q4 		$969K Buy
16,200
+164
+1% +$9.6K 0.02% 950
2020
Q3 		$964K Buy
16,036
+223
+1% +$13K 0.02% 833
2020
Q2 		$830K Buy
15,813
+1,278
+9% +$53.4K 0.02% 902
2020
Q1 		$487K Hold
14,535
– – 0.01% 999
2019
Q4 		$658K Buy
14,535
+411
+3% +$17.5K 0.01% 1039
2019
Q3 		$538K Buy
+14,124
New +$564K 0.01% 1078

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Mason Street Advisors's PCRX Position: Q1 2021 in Review

Mason Street Advisors sold out of Pacira BioSciences (PCRX) in Q1 2021, closing a stake of 16,200 shares — an estimated $969K sold.

Mason Street Advisors first reported a position in PCRX in Q3 2019 and held it in 6 quarters. The position peaked at $969K in Q4 2020. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2021.

  • Mason Street Advisors reported no remaining Pacira BioSciences position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 16,200 Pacira BioSciences shares in Q1 2021, an estimated $969K.
  • Mason Street Advisors first reported a position in Pacira BioSciences in Q3 2019 and held it in 6 quarters.
  • Mason Street Advisors's Pacira BioSciences position peaked at $969K in Q4 2020.
  • 270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.